Sweet’s Syndrome Accompanied by Coinfection with Multiple Pathogens and Disseminated Mycobacterium phlei Infection Presenting with Osteolytic Destruction During 12 Years of Follow-Up: A Rare Case Report

References

• Browne SK, Burbelo PD, Chetchotisakd P, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med. 2012;367(8):725–734. doi:10.1056/NEJMoa1111160
   PubMed Web of Science ®Google Scholar
• Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2019 update on the classification from the international union of immunological societies expert committee. J Clin Immunol. 2020;40(1):24–64. doi:10.1007/s10875-019-00737-x
   PubMed Web of Science ®Google Scholar
• Browne SK. Anticytokine autoantibody-associated immunodeficiency. Annu Rev Immunol. 2014;32:635–657. doi:10.1146/annurev-immunol-032713-120222
   PubMed Web of Science ®Google Scholar
• Zeng W, Qiu Y, Tang S, Zhang J, Pan M, Zhong X. Characterization of anti–interferon-γ antibodies in HIV-negative patients infected with disseminated talaromyces marneffei and Cryptococcosis. Open Forum Infect Dis. 2019;6(10):ofz208. doi:10.1093/ofid/ofz208
   Web of Science ®Google Scholar
• Hong GH, Ortega-Villa AM, Hunsberger S, et al. Natural history and evolution of anti-interferon-gamma autoantibody-associated immunodeficiency syndrome in Thailand and the United States. Clin Infect Dis. 2020;71(1):53–62. doi:10.1093/cid/ciz786
   Web of Science ®Google Scholar
• Jutivorakool K, Sittiwattanawong P, Kantikosum K, et al. Skin manifestations in patients with adult-onset immunodeficiency due to anti-interferon-gamma autoantibody: a relationship with systemic infections. Acta Derm Venereol. 2018;98(8):742–747. doi:10.2340/00015555-2959
   Web of Science ®Google Scholar
• Tanaka S, Hoshino Y, Sakagami T, Fukano H, Matsui Y, Hiranuma O. Pathogenicity of Mycolicibacterium phlei, a non-pathogenic nontuberculous Mycobacterium in an immunocompetent host carrying anti-interferon gamma autoantibodies: a case report. BMC Infect Dis. 2019;19(1):454. doi:10.1186/s12879-019-4050-z
   Web of Science ®Google Scholar
• Sweet RD. An acute febrile neutrophilic dermatosis. Br J Dermatol. 1964;76:349–356. doi:10.1111/j.1365-2133.1964.tb14541.x
   PubMed Web of Science ®Google Scholar
• Chaowattanapanit S, Choonhakarn C, Chetchotisakd P, Sawanyawisuth K, Julanon N. Clinical features and outcomes of sweet’s syndrome associated with non-tuberculous Mycobacterial infection and other associated diseases. J Dermatol. 2016;43(5):532–536. doi:10.1111/1346-8138.13167
   Web of Science ®Google Scholar
• Mizoguchi M, Matsuki K, Mochizuki M, et al. Human leukocyte antigen in sweet’s syndrome and its relationship to behçet’s disease. Arch Dermatol. 1988;124(7):1069–1073. doi:10.1001/archderm.1988.01670070057019
   Google Scholar
• Yang M, Zhang J, He Z, et al. Lung involvement of 3 cases of idiopathic sweet syndrome and literature review. Zhonghua Jie He He Hu Xi Za Zhi. 2015;38(8):589–594.
   Google Scholar
• Tang M, Huang J, Zeng W, et al. Retrospective analysis of 10 cases of disseminated nontuberculous Mycobacterial disease with osteolytic lesions. Infect Drug Resist. 2021;14:4667–4679. doi:10.2147/IDR.S337956
   Web of Science ®Google Scholar
• Kim CJ, Kim UJ, Kim HB, et al. Vertebral osteomyelitis caused by non-tuberculous mycobacteria: predisposing conditions and clinical characteristics of six cases and a review of 63 cases in the literature. Infect Dis. 2016;48(7):509–516. doi:10.3109/23744235.2016.1158418
   PubMed Web of Science ®Google Scholar
• Kim JH, Jung IY, Song JE, et al. Profiles of extrapulmonary nontuberculous Mycobacteria infections and predictors for species: a multicenter retrospective study. Pathogens. 2020;9(11):949. doi:10.3390/pathogens9110949
   Web of Science ®Google Scholar
• McGee AW Jr, Dean CS, Ignatiuk A, Savelli C, Kleck CJ. Mycobacterium phlei vertebral osteomyelitis. J Am Acad Orthop Surg Glob Res Rev. 2019;3(12):e18.00069. doi:10.5435/JAAOSGlobal-D-18-00069
   Google Scholar
• Chi CY, Lin CH, Ho MW, et al. Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-gamma autoantibodies and disseminated nontuberculous mycobacterial infections. Medicine. 2016;95(25):e3927. doi:10.1097/MD.0000000000003927
   Web of Science ®Google Scholar
• Döffinger R, Helbert MR, Barcenas-Morales G, et al. Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin Infect Dis. 2004;38(1):e10–e14. doi:10.1086/380453
   Web of Science ®Google Scholar
• Valour F, Perpoint T, Senechal A, et al. Interferon-gamma autoantibodies as predisposing factor for nontuberculous mycobacterial infection. Emerg Infect Dis. 2016;22(6):1124–1126. doi:10.3201/eid2206.151860
   Web of Science ®Google Scholar
• Chawansuntati K, Rattanathammethee K, Minireview: WJ. Insights into anti-interferon-gamma autoantibodies. Exp Biol Med. 2021;246(7):790–795. doi:10.1177/1535370220981579
   Web of Science ®Google Scholar
• Kiratikanon S, Phinyo P, Rujiwetpongstorn R, et al. Adult-onset immunodeficiency due to anti-interferon-gamma autoantibody-associated sweet syndrome: a distinctive entity. J Dermatol. 2022;49(1):133–141. doi:10.1111/1346-8138.16202
   Web of Science ®Google Scholar
• Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous Mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416. doi:10.1164/rccm.200604-571ST
   PubMed Web of Science ®Google Scholar
• Laisuan W, Pisitkun P, Ngamjanyaporn P, Suangtamai T, Rotjanapan P. Prospective pilot study of cyclophosphamide as an adjunct treatment in patients with adult-onset immunodeficiency associated with anti-interferon-γ autoantibodies. Open Forum Infect Dis. 2020;7(2):ofaa035. doi:10.1093/ofid/ofaa035
   Web of Science ®Google Scholar
• Koizumi Y, Sakagami T, Nishiyama N, et al. Rituximab restores IFN-γ-STAT1 function and ameliorates disseminated Mycobacterium avium infection in a patient with anti-interferon-γ autoantibody. J Clin Immunol. 2017;37(7):644–649. doi:10.1007/s10875-017-0425-3
   Web of Science ®Google Scholar